Pharma and biotech executives and professionals, service providers and allied agencies are invited to attend the BioPharma Formulation & Delivery Nexus on November 14-25, 2024, in London, UK.  Scientists, C-level executives, directors, and vice presidents from prestigious organizations in Europe and North America will attend the event. Industry leaders can harness the reach of the event platform to educate, learn and interact with an engaging audience from the BioPharma spectrum.

BioPharma Nexus is focused on creating a union among leading pharmaceutical and biotechnology entities, along with service providers. Their objective is to provide high-quality healthcare to patients all over the globe. At the BioPharma Nexus conferences, players can explore, discover and generate…

Read More>>

To learn more, please visit https://ibn.fm/BUldQ.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN